Hypogonadotropic Hypogonadism Cell Models for Research

Hypogonadotropic hypogonadism (HH) is a rare disorder characterized by delayed or absent puberty and infertility due to deficient secretion of gonadotropin-releasing hormone (GnRH) or gonadotropins. The prevalence is estimated at 1 in 4,000 to 1 in 10,000 individuals, with a male-to-female ratio of about 4:1. The condition can be congenital (e.g., Kallmann syndrome) or acquired (e.g., due to tumors, trauma, or infiltrative diseases). Clinical impact includes infertility, osteoporosis, and psychological distress. Early diagnosis and hormone replacement therapy can mitigate complications, but genetic causes remain poorly understood.

HH is an excellent model for studying neuroendocrine regulation, GnRH neuronal development, and puberty. The disease has a strong genetic component, with over 30 genes implicated, including KAL1, FGFR1, PROKR2, KISS1R, and TAC3. Public datasets such as the Human Gene Mutation Database (HGMD) and ClinVar provide extensive variant information. Open questions include the precise molecular mechanisms of GnRH neuron migration, the role of epigenetic factors, and genotype-phenotype correlations. Gene-edited cell models are essential for functional validation of candidate genes and for drug screening.

While HH is not a cancer, the underlying pathways are critical for neuroendocrine function. Key pathways include:

• • GnRH signaling pathway: GnRH binds to its receptor on pituitary gonadotropes, leading to secretion of LH and FSH.
• • Kisspeptin signaling: Kisspeptin (KISS1) binds to KISS1R (GPR54) to stimulate GnRH secretion.
• • FGFR1 signaling: Fibroblast growth factor receptor 1 (FGFR1) is involved in GnRH neuron development and migration.
• • Prokineticin signaling: PROK2 and PROKR2 are essential for GnRH neuron migration.

These pathways are interconnected and mutations in any component can disrupt the hypothalamic-pituitary-gonadal axis.

Data from ClinVar and COSMIC.

The GnRH neuronal network is regulated by multiple signaling cascades:

• • Kisspeptin/KISS1R: Activates Gq/11, leading to PLC, IP3, and calcium mobilization.
• • FGFR1: Activates MAPK/ERK and PI3K/AKT pathways, promoting cell survival and migration.
• • Prokineticin/PROKR2: Activates Gq and G12/13, modulating cell migration.
• • Neurokinin B/TACR3: Involved in pulsatile GnRH secretion.

Dysregulation of these networks leads to impaired GnRH neuron function and hypogonadism.

Organoids derived from human induced pluripotent stem cells (iPSCs) can recapitulate GnRH neuron development and are useful for studying migration and function.

• • GnRH neuron-specific knockout mice: e.g., GnRH-Cre crossed with floxed genes.
• • Hypogonadal (hpg) mice: Spontaneous GnRH gene deletion.
• • Kiss1r knockout mice: Model of idiopathic hypogonadotropic hypogonadism.
• • Zebrafish models: Used for high-throughput drug screening.

These models are valuable for in vivo studies but are time-consuming and costly.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise mutations in HH-associated genes. For example:

• • KISS1R knockout cell line: Generated in GN11 or GT1-7 cells to study loss of kisspeptin signaling.
• • FGFR1 knockout cell line: To investigate impaired GnRH neuron migration.
• • KAL1 knockout cell line: To model Kallmann syndrome.
• • Point-mutation knock-in lines: e.g., KISS1R R331X or FGFR1 P722H, to study specific pathogenic variants.

These models are commercially available and sequence-verified, accelerating research by providing consistent, reproducible tools for functional studies and drug screening.

Gene-edited cell lines allow functional validation of candidate genes identified in patient cohorts. For example, knocking out KISS1R in GN11 cells can confirm its role in GnRH secretion. Knock-in of a pathogenic variant can reveal dominant-negative or gain-of-function effects. These models are essential for genotype-phenotype correlation studies.

Isogenic pairs (wild-type vs. knockout) can be used to screen for compounds that rescue GnRH secretion or neuronal migration. For instance, a KISS1R knockout cell line can be used to identify agonists that bypass the receptor. Resistance to hormonal therapy can be modeled by exposing cells to chronic GnRH analogs and selecting for resistant clones.

CRISPR-based synthetic lethality screens can identify genes that, when knocked out, are lethal only in HH-mutant cells. This can reveal novel therapeutic targets. Additionally, gene-edited cells can be used to discover biomarkers for early diagnosis or monitoring of treatment response.